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CRIPTO and its signaling partner GRP78 drive the metastatic
phenotype in human osteotropic prostate cancer
E Zoni1,2, L Chen3, S Karkampouna1,2, Z Granchi4, EI Verhoef5, F La Manna1,2, J Kelber6, RCM Pelger1, MD Henry7, E Snaar-Jagalska2,
GJLH van Leenders5, L Beimers8, P Kloen9, PC Gray10, G van der Pluijm1 and M Kruithof-de Julio1,2
CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high
expression of CRIPTO correlates with poor survival in stratiﬁed risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling
partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic
ALDHhigh sub-population of PC-3M-Pro4Luc2 PCa cells compared with non-metastatic ALDHlow. Coculture of the osteotropic PC-3M-
Pro4Luc2 PCa cells with differentiated primary human osteoblasts induced CRIPTO and GRP78 expression in cancer cells and
increases the size of the ALDHhigh sub-population. Additionally, CRIPTO or GRP78 knockdown decreases proliferation, migration,
clonogenicity and the size of the metastasis-initiating ALDHhigh sub-population. CRIPTO knockdown reduces the invasion of PC-3M-
Pro4Luc2 cells in zebraﬁsh and inhibits bone metastasis in a preclinical mouse model. These results highlight a functional role for
CRIPTO and GRP78 in PCa metastasis and suggest that targeting CRIPTO/GRP78 signaling may have signiﬁcant therapeutic
potential.
Oncogene (2017) 36, 4739–4749; doi:10.1038/onc.2017.87; published online 10 April 2017
INTRODUCTION
Prostate cancer (PCa) is the second most common cancer in men
worldwide.1 While current treatments of primary tumors are
initially very effective, these beneﬁcial responses are often
followed by tumor recurrence and incurable bone metastases.
Therefore, identifying molecular mediators of PCa relapse and
metastasis will aid in the development of therapies for this deadly
phase of the disease.
CRIPTO (TDGF1, CRIPTO-1) is a small, GPI-anchored/secreted
fetal oncoprotein that has important roles in regulating stem cell
differentiation, embryogenesis, tissue growth and remodeling.2
CRIPTO promotes transformation, migration, invasion and angio-
genesis and its misregulation can contribute to cancer develop-
ment and progression in multiple malignancies, including breast
cancer and PCa, which are both characterized by osteotropism in
their metastatic stage.3,4 CRIPTO modulates crucial pathways that
regulate bone metastasis such as the tumor growth factor-β
(TGF-β) pathway5 and functions as an obligatory coreceptor for
Nodal, a TGF-β superfamily member that promotes epithelial-to-
mesenchymal transition (EMT) in PCa.5–7 Glucose-regulated
protein 78 (GRP78) was identiﬁed as a CRIPTO-binding protein
and essential mediator of CRIPTO signaling.8–10 GRP78 is well
established as a key survival factor in development and cancer 8,9
and, notably, upregulation of GRP78 has been associated with the
development of castration-resistant PCa.11 While CRIPTO was
reported to impact primary human prostate adenocarcinomas,6 its
role in driving castration-resistant PCa and PCa bone metastasis
remains unknown.
Here, we investigated the roles of CRIPTO and GRP78 in
aggressive, metastatic human PCa cells both in vitro and in vivo
using an embryonic zebraﬁsh model and a preclinical mouse
model of experimentally induced PCa bone metastasis. We found
that CRIPTO and GRP78 are upregulated in clinical samples of PCa
metastases from human patients and in the highly metastatic
ALDHhigh stem/progenitor-like sub-population of a human
castration-resistant PCa cell line.12,13 We further demonstrate that
knockdown of CRIPTO or GRP78 in these cells decreases the size of
the stem/progenitor-like sub-population and also inhibits their
extravasation following inoculation into zebraﬁsh and their
metastatic potential in a preclinical mouse model of bone
metastasis in vivo. Taken together, these ﬁndings provide new
evidence that CRIPTO and GRP78 may drive metastatic PCa and
highlight the therapeutic potential of targeting the cell surface
CRIPTO/GRP78 complex for the treatment of this deadly disease.
RESULTS
CRIPTO is highly expressed in metastases from human PCa
patients and correlates with poor survival
CRIPTO and its signaling partner GRP78 have been shown to have
important roles in tumor development and bone metastasis.14 We
investigated the correlation of survival with CRIPTO expression in
independent sets of public PCa data sets (GSE21032 and
GSE1064515,16). In both data sets, CRIPTO expression was
associated with poor prognosis (Figures 1a and b (top); hazard
ratio (HR) = 1.87 and P= 0.001 for GSE10645 and HR= 2.2 and
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P= 0.06 for GSE21032). Additionally, in both data sets, the
expression of CRIPTO in stratiﬁed risk groups was signiﬁcantly
higher in the high- vs low-risk group (Figures 1a and b (bottom);
P= 1.13e− 103 for GSE10645 and P= 3.68e− 23 for GSE21032).
We further investigated the expression of CRIPTO and GRP78
in the Ramaswamy Multi-cancer data set from Oncomine
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(Compendia Bioscience, Waltham, MA, USA), which compares PCa
metastasis to primary sites in 76 samples17 and includes quantiﬁed
differential gene expression patterns between human primary
tumors and metastatic lesions arising from corresponding primary
site. Additionally, to investigate the levels of CRIPTO in site-speciﬁc
metastases, we also analyzed a previously published data set
(Chandran prostate GSE6752) where 31 prostate specimens
(10 primary and 21 hormone-refractory metastatic) were
included.18 We found that CRIPTO and GRP78 are signiﬁcantly
upregulated in metastatic lesions arising from human prostate
tumors, compared with primary sites in human PCa (Figures 1c,
P= 7.15e− 4 for CRIPTO and P= 0.03 for GRP78; Supplementary
Figures 1A and B). Subsequently, we investigated the expression
of CRIPTO in PCa bone metastases by immunostaining of parafﬁn-
embedded sections of bone metastases freshly isolated from
patients. We detected signiﬁcant expression of CRIPTO and
colocalization of CRIPTO with cytokeratin-18 in serial sections
from each of the 13 specimens analyzed (Figure 1d). Taken
together, these data demonstrate that CRIPTO is selectively
expressed in aggressive and metastatic PCa and that its
expression correlates with poor prognosis.
Coculture with primary human osteoblasts augments the
ALDHhigh sub-population, upregulates CRIPTO and GRP78 and
promotes the metastatic phenotype of PCa cells
We previously reported that the ALDHhigh sub-population of
PC-3M-Pro4Luc2 cells displays stem/progenitor-like properties and
is highly metastatic relative to its ALDHlow counterpart.12 CRIPTO
and GRP78 are expressed in human PCa cell lines (PC-3M-
Pro4Luc2 and C4-2B cells) (Figures 2a–c) and given their known
roles in regulating tumor aggressiveness, we tested if CRIPTO and
GRP78 are selectively expressed in the ALDHhigh sub-population.
Quantitative real-time PCR (qRT–PCR) (Figure 2d) and protein
analysis (Figures 2e and f) on selected sub-population of cells
isolated after viable cell sorting showed that GRP78 levels were
indistinguishable in both sub-populations but that CRIPTO was
more highly expressed in the ALDHhigh sub-population than in the
ALDHlow (Po0.01 for CRIPTO). This result is consistent with a role
for CRIPTO in promoting PCa growth and metastasis.
In PCa and other cancers, the osteoblastic microenvironment
functions as premetastatic niche by attracting bone-metastasizing
tumor cells.19–21 We developed a model of the bone metastatic
niche in which primary human osteoblasts are cocultured with
PC-3M-Pro4Luc2 cells in vitro. Differentiation of the human
osteoblasts was conﬁrmed by Alizarin red staining
(Supplementary Figure 2A). We found that in the presence of
osteoblasts, the size of the ALDHhigh sub-population increases
markedly compared with the size of the ALDHhigh sub-population
in PCa cells alone (coculture = 60 vs control = 15%, Po0.05)
(Figure 2g). This effect appeared to be osteoblast-speciﬁc as
coculture of PCa cells with a non-osteoblast cell line
(HEK293T cells) failed to reproduce the signiﬁcant increase in
the percentage of ALDHhigh cells (Supplementary Figure 2b).
Moreover, mRNA analysis after viable cell sorting of ﬂuorescently
labeled PC-3M-Pro4Luc2 cells (cocultured cells compared with
control) showed signiﬁcant increase in CRIPTO (Po0.05) and
GRP78 expression (Figure 2h). In addition, conditioned medium
(CM) generated in the absence of serum, collected from
osteoblasts, increased the migratory capability of PC-3M-
Pro4Luc2 cells and the increase was directly proportional to the
concentration of the CM used (Po0.001 for 50 CM+50% not-CM
vs control; Po0.001 for 100% CM vs control and Po0.001 for
100 CM vs 50% CM; Figure 2i). In line with these observations,
administration of osteoblast CM led to the acquisition of a motile,
mesenchymal phenotype in PC-3M-Pro4Luc2 PCa cells as indi-
cated by a decrease in the mRNA expression of the epithelial
marker E-cadherin (Po0.05), a concomitant increase in the
mesenchymal markers ZEB1 and ZEB2 (Po0.05 for both genes)
(Supplementary Figure 2C) and a signiﬁcant reduction of the ratio
E-cadherin/vimentin (Po0.05) and ratio E-cadherin/N-cadherin
(Figure 2j). Taken together, these data indicate that secreted
factors derived from osteoblasts promote the metastatic pheno-
type of PCa cells and increases their expression of CRIPTO
and GRP78.
CRIPTO and GRP78 maintain aggressiveness of human PCa cells
in vitro
To test the function of CRIPTO and GRP78 in human PCa cells, we
generated stable knockdown lines in PC-3M-Pro4Luc2 and C4-2B
cells and validated reduced expression of CRIPTO and GRP78 by
qRT–PCR, western blot and FACS analysis (Figures 3a and b and
Supplementary Figures 3A–E). As previously shown by others in
PC3 cells and consistent with the extensive post-translational
modiﬁcation of CRIPTO, we detected two protein bands of ~ 17
and 25 kDa5,22 (Figure 3b). CRIPTO knockdown lines (short hairpin
RNA (shRNA) no. 2 and 3) both show decreased cell proliferation
(Po0.001 at 24 h for shRNA no. 2 and Po0.001 at 24, 48 and 72 h
for shRNA no. 2 and 3) (Figure 3c). We conﬁrmed the acquisition of
this phenotype upon CRIPTO silencing by an additional pool of
independent siRNAs targeting CRIPTO (Supplementary Figures 3F
and 3G). No effect on cell proliferation was observed in the C4-2B
CRIPTO knockdown cells (Supplementary Figure 4A). The PC-3M-
Pro4Luc2 CRIPTO knockdown cells also had a signiﬁcantly reduced
percentage of metastatic, stem cell-like ALDHhigh cells relative to
non-targeted (NT) control cells (Po0.05 for shRNA no. 2 and
P=NS for shRNA no. 3; Figure 3d). GRP78 knockdown similarly
displayed reduction of the size of ALDHhigh sub-population of cells
(Po0.05 for shRNA no. 1 and P=NS for shRNA no. 2)
(Supplementary Figure 4B).
We previously reported that the ALDHhigh sub-population of
PC-3M-Pro4Luc2 is enriched for cells with increased clonogenicity
and migratory properties relative to the ALDHlow cells.12 Con-
sistent with our ALDEFLUOR data, we show that PC-3M-Pro4Luc2
CRIPTO knockdown with shRNA no. 2 signiﬁcantly reduces
clonogenicity, as measured by the number and area of colonies
produced (Po0.05) (Supplementary Figure 4C). This effect
appeared to be speciﬁc since transfection of a non-targetable
mouse CRIPTO expression construct resulted in signiﬁcant rescue
of the loss of clonogenicity caused by the CRIPTO shRNA
(Po0.001 for colony number and Po0.05 for colony area)
(Figure 3e). GRP78 knockdown in PC-3M-Pro4Luc2 human PCa
cells also resulted in a decrease in the number of colonies
(Po0.05) and a similar trend was shown for colony area
(Supplementary Figure 4D). Finally, CRIPTO knockdown signiﬁ-
cantly reduced the migratory capability of both cell lines (Po0.05
and Po0.01 respectively; Figures 4a and b), these ﬁndings were
Figure 1. CRIPTO is expressed in PCa metastasis from human patients and correlates with poor patient prognosis. (a and b) Top panels:
Kaplan–Meier survival curves of censored Cox analysis in Kollemeyer–Jenkins prostate and Taylor-MSKCC prostate database stratiﬁed by
maximized CRIPTO expression risk groups. Red= high expression; green= low expression. Bottom panels: CRIPTO expression stratiﬁed by risk
groups. Red=high-risk and high CRIPTO expression; green= low-risk and low CRIPTO expression. Data accessed from http://bioinformatica.
mty.itesm.mx:8080/Biomatec/SurvivaX.jsp. (c) CRIPTO is signiﬁcantly upregulated in PCa metastasis. The Ramaswamy Multi-cancer publicly
available data set and the Chandran data set (data accessed from www.oncomine.org) was used for analysis. Data are represented in Tukey's
plot format for each individual patient, respectively. (d) Representative images of serial sections of PCa bone metastasis stained for
cytokeratin-18 (CK18) and CRIPTO and counter stained with hematoxylin (N= 13) at lower (×10) and higher (×40, see inserts) magniﬁcation.
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Figure 2. Coculture with human osteoblasts (OBs) increases expression of CRIPTO and GRP78 and stem cell-like properties of human PCa cells.
(a–c) CRIPTO and GRP78 expression in PC-3M-Pro4Luc2 and C4-2B human PCa cell lines. Error bars± s.e.m. (d) CRIPTO and GRP78 expression in
highly metastatic sub-population of ALDHhigh PCa cells vs low metastatic ALDHlow in PC-3M-Pro4Luc2 cells. Error bars± s.e.m. (e and f) CRIPTO
but not GRP78 protein is increased in highly metastatic sub-population of ALDHhigh PCa cells vs low metastatic ALDHlow in PC-3M-Pro4Luc2 cells
isolated after viable cell sorting. (g) Direct coculture of ﬂuorescently labeled PC-3M-Pro4Luc2 human PCa cells (T; 900 000 cells seeded per petri
dish) with differentiated human OBs (conﬂuent layer of differentiated cells per petri dish) for 48 h increases the size of the ALDHhigh sub-
population in PCa cells. Each samples is gated according to its internal control (small panel represented in the top left part of the plot). Error
bars± s.e.m. Two experiments are shown. Assay replicated more than three times in the laboratory. (h) mRNA analysis shows increased CRIPTO
and GRP78 expression after coculture. Error bars± s.e.m. Two experiments are shown. Assay replicated more than three times in the laboratory.
(i) CM from human osteoblast, generated in the absence of serum, enhances migration of PC-3M-Pro4Luc2 human PCa cells. Error bars± s.e.m.
Two experiments are shown. Assay replicated three times in the laboratory. (j) Coculture of PC-3M-Pro4Luc2_dTomato PCa cells for 48 h with
human osteoblast induces a shift to mesenchymal phenotype (decrease in ratio E-cadherin/vimentin and E-cadherin/N-cadherin). Error
bars±s.e.m. Two experiments are shown, assay replicated more than three times in the laboratory. *Po0.05, **Po0.01, *** and $$$Po0.001.
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conﬁrmed by an independent pool of siRNAs (Supplementary
Figure 4E). Signiﬁcant rescue of the effects of shRNA knockdown
could be again achieved by the non-targetable CRIPTO expression
construct solely in PC-3M-Pro4Luc2 cells (Figures 4c and d). GRP78
knockdown in PC-3M-Pro4Luc2 cells also resulted in a signiﬁcant
reduction of migratory potential (Po0.001 for both shRNAs)
(Supplementary Figure 4F). Additionally, CRIPTO knockdown in
PC-3M-Pro4Luc2 cells signiﬁcantly reduced the migration towards
osteoblast CM (Supplementary Figures 5A and B). Taken together,
these data suggest that CRIPTO and GRP78 are required to
maintain an aggressive phenotype of PC-3M-Pro4Luc2 cells.
CRIPTO promotes EMT and invasiveness of human PCa cells
EMT is strongly associated with tumor cell invasion and CRIPTO
was recently reported to promote EMT in human PCa.6 Consistent
with this study, we found that CRIPTO overexpression in PC-3M-
Pro4Luc2 and C4-2B cells (Supplementary Figures 6A and B)
causes a strong and signiﬁcant downregulation of the epithelial
marker E-cadherin (Po0.05) at the mRNA level in both cell lines
and an increase in the mesenchymal markers vimentin, SNAIL2
and TWIST in PC-3M-Pro4Luc2 cells (Po0.05, Po0.05 and
Po0.01, respectively) and ZEB1 in C4-2B cells (Supplementary
Figures 6c and d). CRIPTO overexpression caused a strong and
signiﬁcant decrease in the ratio of E-cadherin/vimentin (Po0.01)
in both PCa cell lines (Figures 4e and f). Taken together, these data
support a role for CRIPTO in promoting EMT and the invasive
phenotype in PC-3M-Pro4Luc2 and C4-2B cells. Additionally, and
consistent with previous reports,8,23 we have found that CRIPTO
modulates TGF-β signaling in our model system (Supplementary
Figure 6E). These data are consistent with previous reports
documenting extensive interaction of CRIPTO with the TGF-β
pathway and other signaling networks.24,25
We have previously shown that zebraﬁsh can be used to
evaluate effectively migration and invasion of human PCa cells
and the interaction between PCa cells and the vasculature at the
single-cell level in vivo.13,26 Clear detection of extravasating tumor
cells in this system is facilitated by the fact that the vascular
system of zebraﬁsh embryos is completely functional and the
embryos are transparent.27 We tested the role of CRIPTO and
GRP78 in PCa cell extravasation and metastasis by injecting
ﬂuorescently labeled PC-3M-Pro4Luc2 cells with CRIPTO or GRP78
knocked down into the circulatory system of zebraﬁsh embryos.13
In the ﬁrst hours, disseminated cells arrested in the host
vasculature and then we observed extravasation from 12 hpi
(hours postimplantation) and perivascular tumor cells in multiple
foci including the intersegmental vessels, the optic veins, the
dorsal aorta and the caudal vein. The perivascular tumor cells
invaded the neighboring tail ﬁn exclusively at the posterior ventral
end of the hematopoietic tissue. At day 4 postimplantation (4 dpi),
CRIPTO knockdown caused a signiﬁcant reduction in extravasation
Figure 3. CRIPTO knockdown causes loss of the stem cell-like phenotype in PCa cells. (a and b) qRT–PCR and Western blot analysis of CRIPTO
expression in control (scrambled shRNA, NT) PC-3M-Pro4Luc2 (ﬁrst lane) and CRIPTO knockdown PC-3M-Pro4Luc2 cells with shCRIPTO no.
1–3, derived from different shRNA constructs. Two bands of, respectively, 25 kDa (Native) and 17 kDa (Core) for CRIPTO are detected as shown
previously (see Results). (c) Knockdown of CRIPTO affects the proliferation in PC-3M-Pro4Luc2. Error Bars± s.e.m. (d) CRIPTO knockdown leads
to a decrease in the size of ALDHhigh sub-population in PC-3M-Pro4Luc2 cells. Error Bars± s.e.m. (e) CRIPTO knockdown affects clonogenic
ability and CRIPTO overexpression is capable of reversing this phenotype in PC-3M-Pro4Luc2. Error bars± s.e.m. *,$,#Po0.05; **,$$Po0.01;
***Po0.001.
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and tumor growth compared with control cells with scrambled
shRNA (Figures 5a–c). Similarly, GRP78 knockdown cells displayed
a signiﬁcant reduction in the tumor growth into the tail ﬁn after
invasion from hematopoietic tissue compared to control cells
(Supplementary Figures 7A and B). However, invasion was not
signiﬁcantly different in GRP78 knockdown cells compared with
control cells (Supplementary Figure 7C). Taken together, these
data support our in vitro ﬁndings and reinforce the hypothesis that
CRIPTO/GRP78 signaling has an important role in the maintenance
of an invasive and aggressive phenotype in human PCa.
CRIPTO knockdown decreases metastasis formation in preclinical
mouse model of PCa bone metastasis
We previously demonstrated that intracardiac injection of
luciferase-expressing PC-3M-Pro4Luc2 cells in mice results in bone
metastasis.12 Here, we used this preclinical mouse model to test
the role of CRIPTO in mediating the metastatic activity of these
PCa cells. CRIPTO knockdown cells or control cells with a
scrambled shRNA were injected into the left cardiac ventricle of
nude mice (Balb/c nu/nu) and bioluminescence, which reﬂects
tumor size, was measured weekly for the course of the
experiment. The same batch of cells injected was functionally
tested in vitro (Supplementary Figure 8A). Quantiﬁcation of
bioluminescent images (Figures 6a and b, week 5, Po0.05)
showed signiﬁcant reduction in metastasis formation and the total
number of metastases (Figure 6c, week 5, Po0.01), speciﬁcally
bone metastases (Figure 6d, week 5, Po0.01), in mice inoculated
with CRIPTO knockdown cells compared with mice injected with
control cells. No effect on weight of the animals was measured
(Supplementary Figure 8B). This result is consistent with the other
ﬁndings outlined above and suggests that CRIPTO is required for
bone metastasis in a mouse model of human PCa.
Figure 4. CRIPTO overexpression promotes PCa cell migration and rescues effects of CRIPTO knockdown. (a and b) CRIPTO Knockdown
signiﬁcantly reduces cell migration in PC-3M-Pro4Luc2 and C4-2B cells and CRIPTO overexpression is capable of rescuing completely (PC-3M-
Pro4Luc2) or partially (C4-2B) the phenotype. Quantiﬁcation is shown in (c and d) Error bars± s.e.m. (e) mRNA analysis in PC-3M-Pro4Luc2 cells and
C4-2B (f) after 48 h of CRIPTO overexpression shows decrease in E-cadherin/vimentin ratio. Error bars± s.e.m. $Po0.05, **Po0.01 and ***Po0.001.
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DISCUSSION
This study presents evidence for a role of CRIPTO and GRP78 in the
regulation of the invasive program of PCa cells that maintains
stem cell-like and aggressive phenotypes in human PCa. Our
demonstration that CRIPTO is strongly upregulated in high-risk
patient groups compared with low-risk groups and that it
correlates with poor survival highlight the signiﬁcance of these
proteins in metastatic PCa. Importantly, the selective expression of
CRIPTO and GRP78 in PCa metastases was substantiated by the
analysis of publicly available data sets17,18 and reinforced by our
analysis on 13 samples of PCa bone metastasis derived from
castration-resistant PCa patients.
CRIPTO/GRP78 signaling is known to regulate stem cells and
tumor cells25 and our results suggest that this signaling may
promote the acquisition of a metastatic phenotype in PCa. This
phenotype includes the ability of PCa cells to invade the
supportive stroma and neighboring tissues to allow subsequent
formation of bone metastases at distant sites.28 CRIPTO/GRP78
signaling may also have a speciﬁc role in metastasis by facilitating
initial colonization of the bone by PCa cells. Remarkably, we also
observe a decline in the number of bone foci in the ﬁrst
10–15 days of the mouse metastasis experiments, followed by
much stronger growth of control tumor cells in the bone relative
to the CRIPTO knockdown cells. These data are in line with our
previous study, which shows a similar kinetic29 and support the
hypothesis that only a small percentage of prostate cancer cells
possess the ability to reach efﬁciently the bone, survive in the
bone microenvironment and establish a new growth. Our data
further suggest that this sub-population of PCa cells has stem/
progenitor-like properties that depend on CRIPTO expression.30
The ALDHhigh sub-population of PC-3M-Pro4Luc2 cells is
enriched for tumor-initiating cells with metastatic potential and
generally accounts for a small percentage of all tumor cells.12,13
Here, we show that these highly metastatic ALDHhigh cells have
higher levels of CRIPTO protein expression compared with
non-stem cell-like, non-metastatic ALDHlow cells. This ﬁnding
supports our hypothesis that CRIPTO is restricted to a small sub-
population of cells characterized by high metastatic ability, similar
to what was recently shown in breast cancer.31 Our results also
support the notion that CRIPTO signaling promotes EMT6,7 and the
migratory and invasive phenotype in PCa cells associated with a
switch from a sessile, epithelial state to a motile, mesenchymal
phenotype. Indeed, transcriptional analysis following CRIPTO
overexpression reveals the emergence of an 'EMT signature'
characterized by a marked reduction in the expression of the
epithelial marker E-cadherin paralleled by a signiﬁcant increase in
the expression of the mesenchymal markers vimentin, Snail2
and Twist.
The activation of the bone stroma by metastatic cells alters the
physiological balance between osteoblast-mediated bone forma-
tion and osteoclast-mediated bone resorption during bone
metastatic colonization.32 Strikingly, we found that coculture of
PCa cells with human osteoblasts, which are important cellular
constituents of the bone metastatic niche,32 induced a signiﬁcant
increase in CRIPTO and GRP78 mRNA expression in the tumor
cells. Osteoblasts have previously been reported to promote the
aggressiveness of osteolytic human PCa cells in vitro.19 These
ﬁndings are in line with our data showing that osteoblasts
promote the metastatic phenotype of PCa cells by causing
expansion of the ALDHhigh sub-population, increasing tumor cell
migration and inducing expression of CRIPTO and GRP78. In light
of previous studies demonstrating that CRIPTO binds cell surface
GRP78 and that this interaction is required for CRIPTO signaling,
our results suggest that CRIPTO and GRP78 function cooperatively
to regulate the interaction between tumor cells and osteoblasts
within the bone microenvironment. However, given the complex-
ity of the bone metastatic niche, we focused primarily on the role
of CRIPTO and GRP78 in the maintenance of an aggressive and
metastatic phenotype in PCa cells. Additional experiments are
required to elucidate the interactions between PCa cells and the
Figure 5. CRIPTO knockdown reduces invasion and tumor growth of human PCa cells in vivo. (a) PC-3M-Pro4Luc2_dTomato human PCa cells
with scrambled shRNA control (NT) and shCRIPTO no. 2 shRNAs were injected into the duct of Cuvier to monitor extravasation and formation
of distant growth in vivo (30 embryos injected per group). (b) CRIPTO knockdown reduces whole-body tumor burden at 4 dpi (days post
injection). Error bars± s.e.m. (c) CRIPTO knockdown reduces the number of extravasated cells at 1 and 4 dpi at the caudal hematopoietic
tissue. Error bars± s.e.m. **Po0.01 and ***Po0.001.
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different components of the bone microenvironment in mechan-
istic detail.
Although PCa is manageable if detected early, the castration-
resistant stage of the disease is associated with high morbidity
and mortality because of bone metastases. Therefore, it is critical
to identify and target pathways that contribute to the dissemina-
tion and generation of PCa bone micrometastases. In this study,
we demonstrate that CRIPTO and its signaling mediator GRP78
may have pivotal, functional roles in the acquisition and
maintenance of an invasive, metastatic phenotype in human
prostate cancer (see schematic representation in Figure 7).
Therefore, CRIPTO and GRP78 represent compelling molecules
for targeting and monitoring highly aggressive stem/progenitor-
like PCa cells to prevent the advancement of PCa towards the
castration-resistant and metastatic stage.
MATERIALS AND METHODS
Cell lines
Human osteotropic PCa PC-3M-Pro4,13,29,33 C4-2B cells34 and HEK293T
cells35 were maintained as described previously.29 Human callus tissue
from patients in good health was used to freshly isolate osteoblast
precursor cells. Time to callus harvest ranged from 2 to 3 weeks.
Indications for surgery were nascent (impending) malunion, failure of
ﬁxation or fractures that were operated on in a delayed manner. All
fractures have subsequently successfully healed. Brieﬂy, tissue was minced
in a solution of 2 mg/ml collagenase (Millipore, Billerica, MA, USA) for 3 h at
37 °C and vortexed every 30 min for 1–2 min. The digested tissue was
centrifuged for 5 min two times at 1000 r.p.m. (room temperature) in a
media (Dulbecco's modiﬁed Eagle's medium, Glutamax MEM Non-Essential
Amino Acids (1 × ; Gibco-Thermo Scientiﬁc, Waltham, MA, USA), P/S). Pellet
was resuspended in 0.25% Trypsin solution (Invitrogen, Waltham, MA, USA)
for 1 h at 37 °C. The digested tissue was centrifuged at 1000 r.p.m. for
5 min in media. The cells were plated in osteoblast precursor media
(Dulbecco's modiﬁed Eagle's medium with 10% fetal calf serum, 1%
penicillin–streptomycin and 1% MEM Non-Essential Amino Acids; Gibco-
Thermo Scientiﬁc), passaged ~ 80% conﬂuency and differentiated at
conﬂuence: ascorbic acid (50 mg/ml; Merck, Darmstadt, Germany) was
added in Dulbecco's modiﬁed Eagle's medium with 10% fetal calf serum,
1% penicillin–streptomycin and 1% MEM non-essential amino acids
(Gibco-Thermo Scientiﬁc). Upon detection of nodules (day 11), the
medium was supplemented with β-glycerolphosphate (5 mM; Sigma, St
Louis, MO, USA) and 100 nM dexamethasone. After 3 weeks, cells were
ﬁxed with 4% paraformaldehyde and analyzed for osteogenesis with
Alizarin Red staining (ICN Biomedicals, Santa Ana, CA, USA).36 CM was
generated with incubation time of 48 h, in the absence of serum to
prevent alteration of downstream assays. Cells were maintained at 37 °C
with 5% CO2.
Suppressing CRIPTO and GRP78 with shRNAs
shRNAi for CRIPTO-1 (TRCN004889, TRCN004890 and TRCN004891) and
HSPA5 (TRCN231123, TRCN218611) were obtained from Sigma’s MISSION
library. Lentiviral infection and selection were performed as described
previously.37 Scrambled shRNA (SHC002, NT or control) with the lack of
homology for any mammalian mRNA sequence was used as control.
Figure 6. CRIPTO knockdown inhibits bone metastasis of human PCa cells in vivo. (a) PC-3M-Pro4Luc2 human PCa cells with CRIPTO
knockdown (shCRIPTO no. 2) and shRNA scrambled control (NT) injected in the left ventricle of nude mice. Formation of distant growth was
monitored weekly with bioluminescent imaging (BLI) measurements. Images are representative of six animals for CRIPTO knockdown and four
animals for NT control. (b) Quantiﬁcation of BLI measurements. Difference is signiﬁcant at week 5 (Po0.05 with two-way analysis of variance
(ANOVA)). CRIPTO knockdown is represented in red, and NT control is represented in blue. Error bars± s.e.m. (c) Total number of distant
growths per mouse in mice injected with either CRIPTO knockdown (ShCRIPTO no. 2, red) or control (NT, blue) PC-3M-Pro4Luc2 cells
(*Po0.05; **Po0,01; with two-way ANOVA). Error bars± s.e.m. (d) Total number of distant growths (long bones, mandible, spine) per mouse
in mice injected with either CRIPTO knockdown (ShCRIPTO no. 2, red) or control (NT, blue) PC-3M-Pro4Luc2 cells (**Po0.01; with two-way
ANOVA). Error bars± s.e.m.
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Suppressing CRIPTO expression with siRNAs
Human CRIPTO siRNAs (SR304769A, SR304769B, SR304769C) and negative
controls (SR30004, non-targeting NT) where purchased from OriGene
Technologies (Rockville, MD, USA). PC-3M-Pro4-luc2 were transfected with
a pool of three unique 27mer siRNA duplexes (100 nM each) or (NT) control
(300 nM) siRNA. Proliferation at different time points (0, 24, 48 and 72 h)
and migration were measured 48 h after transfection. Data are represen-
tative of four replicates.
Flow cytometry and aldehyde dehydrogenase assay
A total of 900 000 PC-3M-Pro4Luc2 cells ﬂuorescently labeled with PKH26
Red Fluorescent Cell Linker (Sigma-Aldrich, St Louis, MO, USA) were seeded
in a 10 cm dish on a layer of conﬂuent and differentiated human
osteoblast. After 48 h, cells were washed with phosphate-buffered saline
(PBS), 1 mM EDTA and harvested using trypsin. Fluorescent PC-3M-
Pro4Luc2 cells were separated from osteoblast with BD FACS ARIA (BD
Biosciences, Franklin Lakes, NJ, USA). Non-labeled PC-3M-Pro4Luc2 cells,
labeled PC-3M-Pro4Luc2 tumor-only and osteoblast-only cells were
included as controls. Aldehyde dehydrogenase (ALDH) activity was
measured using ALDEFLUOR Kit (StemCell Technologies, Durham, NC,
USA).12 For knockdown validation, cells were harvested and incubated
with CRIPTO antibody (FAB2772P, clone no. 89633, hCR-1-PE; R&D,
Minneapolis, MN, USA) as per the manufacturer’s protocol. Data were
analyzed with FCS Express Software (De Novo Software,
Los Angeles, CA, USA).
Western blot
Proteins were extracted with RIPA buffer and quantiﬁed using Pierce
Protein Quantiﬁcation Assay (ThermoFisher Scientiﬁc, Waltham, MA, USA).
Ten micrograms of samples were separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to a blotting
membrane using standard techniques. Signal was detected after incuba-
tion with 1:1000 primary antibody (anti-CRIPTO, clone no. PBL6900; Spike
et al.31) and with 1:10 000 secondary horseradish peroxidase antibody
(Promega, Madison, WI, USA).
CRIPTO overexpression
CRIPTO construct, generated as described previously,23 was transfected in
PC-3M-Pro4Luc2 and C4-2B cells with Lipofectamine 2000 (Life Technol-
ogies, Waltham, MA, USA) or with Fugene HD (Promega), respectively,
according to the supplier’s protocol. Data are representative of at least two
independent experiments.
RNA isolation and real-time quantitative PCR
Total RNA was isolated with Trizol Reagent (Invitrogen) and cDNA was
synthesized by reverse transcription (Promega) according to the protocol.
qRT–PCR was performed with Bio-Rad CFX96 (Bio-Rad, Hercules, CA, USA).
Gene expression was normalized to glyceraldehyde-3-phosphate dehy-
drogenase, hypoxanthine-guanine phosphoribosyltransferase and actin.
Primers are listed in Supplementary Table 1.
Luciferase reporter assay
A total of 10 000 PC-3M-Pro4 cells were seeded in a 24-well plate and
Lipofectamine 2000 (Invitrogen) was used according to the manufacturer’s
protocol. Hundred nanograms of CAGA-Luc (TGF-β reporter38) and 10 ng
of CAGGS-Renilla were transfected in combination of CRIPTO over-
expression (100 ng construct per well) 24 h before assessment of
Luciferase. Fireﬂy and Renilla luciferase were measured with Dual
Luciferase Assay (Promega). Data are shown as relative light units and
representative of at least two independent experiments. Fireﬂy luciferase is
normalized for Renilla luciferase.
Proliferation assay
Cells were seeded at density of 1500 cells per well and allowed to grow for
24, 48 and 72 h. Proliferation was assessed with 3-(4,5 dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium after 2 h
incubation at 37 °C (CellTiter96 Aqueous Assay; Promega). Data were
normalized for the number of cells. N=5 per condition, performed in
duplicate experiments.
Transwell migration assay
Migration assays were performed using transwells (8 mm; Corning
LifeSciences, New York, NY, USA).13 For the experiments with CM from
osteoblast, this was diluted in the lower chamber 1:2 with medium (50%
condition) or administered undiluted (100% condition). Data are repre-
sentative of at least two independent experiments, respectively.
Figure 7. Schematic representation of the proposed role of CRIPTO in the metastatic cascade in human prostate cancer. CRIPTO and GRP78
inﬂuence cell proliferation and are highly expressed in highly metastatic stem/progenitor-like cells (ALDHhigh). CRIPTO and GRP78 knockdown
impairs cell migration. CRIPTO- and GRP78-expressing cells are better adapted to surviving in the circulation and of forming distant
metastases in zebraﬁsh and mouse xenograft models.
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Colony formation assay
A total of 100 cells were seeded in 2 ml of medium supplemented with
10% FCII. After 2 weeks, cells were ﬁxed with 4% paraformaldehyde,
colonies stained with 0.1% crystal violet (Sigma-Aldrich) and quantiﬁed.39
Data are representative of at least three independent experiments.
Zebraﬁsh maintenance, embryo preparation and tumor cell
inoculation
Tg(ﬂi1:GFP)i114 zebraﬁsh line40,41 was handled and maintained according to
local animal welfare regulations to standard protocols (http: //www.ZFIN.org).
Two days postfertilization, dechorionized zebraﬁsh embryos were anesthe-
tized and injected with PC-3M-Pro4Luc2 cells ﬂuorescently labeled as
described previously.13,42 Quantiﬁcation of the data was strictly standardized
(automated pixel count of high-resolution images; criteria for quantiﬁcation
of extravasation are 43 cells extravasating per embryo). Zebraﬁsh embryos
(including nonimplanted controls) were maintained at 33 °C, to compromise
between the optimal temperature requirements for ﬁsh and mammalian
cells.43 Data are representative of at least two independent and blind
experiments with ⩾30 embryos per group. Experiments with survival rate of
control group lower than 80% were discarded.
Mice
Male 4–5-week-old athymic nude mice (Balb/c nu/nu n= 10 per group)
purchased from Charles River (L’Arbresle, France) were housed in
ventilated cages under sterile condition and sterile food and water
provided ad libitum. As animals were not treated with any drug,
randomoization was not necessary after cell inoculation. Inoculation of
cells was not done blind. Animal experiment has been approved by the
local committee for animal health ethics and research of Leiden University
(DEC no. 14226) and carried out in accordance with the European
Communities Council Directive 86/609/EEC.
Intracardiac PCa cell injection and whole-body bioluminescent
imaging
A single-cell suspension (1 × 105 PC-3M-Pro4Luc2 CRIPTO knockdown or
NT control cells per 100 μl PBS) was injected into the left ventricle of
anesthetized 5-week-old male nude mice (Balb/c nu/nu). Tumor growth
and metastasis formation was monitored weekly by bioluminescent
imaging using IVIS100 Imaging System (Caliper LifeSciences, Waltham,
MA, USA).12 Analyses of images was performed and quantiﬁed with Living
Image 4.2 (Caliper LifeSciences).
Immunohistochemistry
Five micrometers of formalin-ﬁxed, parafﬁn-embedded sections were
dewaxed and rehydrated using xylene and ethanol, and endogenous
peroxidase was blocked for 20 min in 0.3% H2O2 in PBS. Heat-induced
antigen retrieval was carried out in TRIS-EDTA buffer (pH=9, 4397-9001;
Klinipath, Duiven, The Netherlands) with a pressure cooker (1.2 bar).
Antibodies (anti-CRIPTO, no. PBL6900;31 anti-cytokeratin-18, clone DC10;
Dako, Santa Clara, CA, USA) were diluted 1:2000 in PBS-BSA 0.1% and
incubated overnight at 4 °C. Envision (K500711; Dako) was used to visualize
the antibody, followed by counterstaining with hematoxylin.
Human material
Clinical prostate cancer bone metastases (10 patients) were collected by
the Erasmus MC Tissue Bank under ISO 15189:2007 standard operating
procedures and used according to the Human Tissue and Medical Research
Code for responsible use (2011). For human callus tissue (source of
osteoblast) approval of the Institutional Review Board was obtained and
conﬁrmation that the Medical Research Involving Human Subjects Act
(WMO) does not apply to the present study was obtained by the local
ethics committee since the research was performed on 'waste material'
(three patients) collected from Academisch Medisch Centrum (Amsterdam,
The Netherlands).
Statistical analysis
Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad
software, La Jolla, CA, USA) using two-tailed unpaired t-test or analysis of
variance for comparison between more groups. F-test was used to
compare variances and standard deviations between the groups
compared to meet the assumption of the statistical test. Data are
presented as mean± s.e.m. P-values ⩽ 0.05 were considered to be
statistically signiﬁcant (*Po0.05, **Po0.01 and ***Po0.001).
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